These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 7040093

  • 1. Possibility of three distinct and separable components to fatal graft-vs-host reaction.
    Okunewick JP, Meredith RF, Raikow RB, Buffo MJ, Jones DL.
    Exp Hematol; 1982 Mar; 10(3):277-91. PubMed ID: 7040093
    [No Abstract] [Full Text] [Related]

  • 2. Delayed secondary disease in mice after early or late therapy with anti-thymocyte serum.
    Kinnamon KE, Blackwell LH, Ledney GD.
    Exp Hematol; 1973 Mar; 1(4):202-14. PubMed ID: 4154088
    [No Abstract] [Full Text] [Related]

  • 3. Prevention of graft-versus-host disease by Fab fragments derived from ALG.
    Richie ER, Gallagher MT, Trentin JJ.
    Transplant Proc; 1973 Mar; 5(1):873-6. PubMed ID: 4144467
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM, Waller EK.
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [Abstract] [Full Text] [Related]

  • 8. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
    Li Y, Guo K, Chen Y, Song Z, Li J, Deng L.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
    Glass B, Uharek L, Gaska T, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993 Aug; 12 Suppl 3():S41-7. PubMed ID: 8124257
    [Abstract] [Full Text] [Related]

  • 11. Modification of graft-vs-host disease following bone marrow transplantation in germfree mice.
    Bealmear PM, Mirand EA, Holtermann OA.
    Prog Clin Biol Res; 1983 Aug; 132C():409-21. PubMed ID: 6227014
    [No Abstract] [Full Text] [Related]

  • 12. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Aug; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 13. Long-term survival of murine allogeneic bone marrow chimeras: effect of anti-lymphocyte serum and bone marrow dose.
    Norin AJ, Emeson EE, Veith FJ.
    J Immunol; 1981 Feb; 126(2):428-32. PubMed ID: 7451985
    [Abstract] [Full Text] [Related]

  • 14. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 15. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 Apr; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 16. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 17. [Ways of controlling reactions subserved by non-syngenous immunocompetent cells].
    Kaulen DR, Maianskiĭ DN.
    Usp Sovrem Biol; 1977 Sep 15; 84(1):38-52. PubMed ID: 21493
    [No Abstract] [Full Text] [Related]

  • 18. Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT.
    Rodt H, Kolb HJ, Netzel B, Haas RJ, Wilms K, Götze CB, Link H, Thierfelder S.
    Transplant Proc; 1981 Mar 15; 13(1 Pt 1):257-61. PubMed ID: 7022835
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of the repertoire of T-cell lines and clones specific for minor histocompatibility antigens derived from immunized mice and from mice developing a graft-versus-host reaction.
    Bruley-Rosset M, Miconnet I, Roger T, Seman M, Halle-Pannenko O.
    Transplant Proc; 1993 Feb 15; 25(1 Pt 1):94-5. PubMed ID: 8438503
    [No Abstract] [Full Text] [Related]

  • 20. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H.
    J Immunol; 1995 Mar 15; 154(6):2687-96. PubMed ID: 7876541
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.